Switch theme
Sign up to access all valuation multiples
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
1951
14
Last FY Revenue $224M
Last FY EBITDA $81.8M
$758M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Eczacıbaşı achieved revenue of $224M and an EBITDA of $81.8M.
Eczacıbaşı expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eczacıbaşı valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $224M | XXX | XXX | XXX |
| Gross Profit | XXX | $76.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 34% | XXX | XXX | XXX |
| EBITDA | XXX | $81.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 36% | XXX | XXX | XXX |
| EBIT | XXX | -$1.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1% | XXX | XXX | XXX |
| Net Profit | XXX | $26.2M | XXX | XXX | XXX |
| Net Margin | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | $18.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eczacıbaşı's stock price is TRY 46 (or $1).
Eczacıbaşı has current market cap of TRY 31.6B (or $808M), and EV of TRY 29.6B (or $758M).
See Eczacıbaşı trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $758M | $808M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eczacıbaşı has market cap of $808M and EV of $758M.
Eczacıbaşı's trades at 3.4x EV/Revenue multiple, and 9.3x EV/EBITDA.
Equity research analysts estimate Eczacıbaşı's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eczacıbaşı's P/E ratio is not available.
See valuation multiples for Eczacıbaşı and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $808M | XXX | $808M | XXX | XXX | XXX |
| EV (current) | $758M | XXX | $758M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -554.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 30.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 18.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEczacıbaşı's revenue per employee in the last FY averaged $16.0M, while opex per employee averaged $5.5M for the same period.
Eczacıbaşı's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eczacıbaşı's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eczacıbaşı and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $16.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $5.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eczacıbaşı acquired XXX companies to date.
Last acquisition by Eczacıbaşı was XXXXXXXX, XXXXX XXXXX XXXXXX . Eczacıbaşı acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eczacıbaşı founded? | Eczacıbaşı was founded in 1951. |
| Where is Eczacıbaşı headquartered? | Eczacıbaşı is headquartered in Turkey. |
| How many employees does Eczacıbaşı have? | As of today, Eczacıbaşı has 14 employees. |
| Is Eczacıbaşı publicy listed? | Yes, Eczacıbaşı is a public company listed on IST. |
| What is the stock symbol of Eczacıbaşı? | Eczacıbaşı trades under ECILC ticker. |
| When did Eczacıbaşı go public? | Eczacıbaşı went public in 1990. |
| Who are competitors of Eczacıbaşı? | Similar companies to Eczacıbaşı include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Eczacıbaşı? | Eczacıbaşı's current market cap is $808M |
| Is Eczacıbaşı profitable? | Yes, Eczacıbaşı is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
